AIM: The aim of this study was to define TAC1 and TACR1 methylation profiles for head and neck squamous cell carcinoma (HNSCC) tumors at diagnosis and follow-up and to evaluate their prognostic significance and value as a biomarker of recurrence. MATERIALS AND METHODS: TAC1 and TACR1 expression was measured in a panel of cell lines by quantitative RT-PCR. The TAC1 and TACR1 promoter methylation status was determined by quantitative methylation-specific PCR. RESULTS: Methylation was associated with TAC1 and TACR1 transcription inhibition. TAC1 methylation in 49/100 (49 %) of HNSCC tumor specimens significantly correlated with p16 methylation (P = 0.010), E-cadherin methylation (P = 0.041), galanin methylation (P = 0.037), and disease-free survival (P = 0.002). Stage III and IV patients manifesting TAC1 hypermethylation had significantly shorter survivals than did patients without TAC1 methylation (P = 0.022). TACR1 methylation in 34/100 (34 %) cases was significantly correlated with galanin methylation (P = 0.014) and GALR1 methylation (P = 0.004). TAC1 promoter hypermethylation was statistically correlated with reduced disease-free survival (log-rank test, P = 0.002). In multivariate logistic-regression analysis, methylation of TAC1 and of the gene pair TAC1 and TACR1 was associated with an odds ratio for recurrence of 3.35 (95 % CI, 1.37-8.19; P = 0.008) and 5.09 (95 % CI, 1.44-18.02; P = 0.011), respectively. CONCLUSION: CpG hypermethylation is a likely mechanism of TAC1 and TACR1 gene inactivation, supporting the hypothesis that TAC1 and TACR1 play a role in the tumorigenesis of HNSCC and that this hypermethylation may serve as an important biomarker.
AIM: The aim of this study was to define TAC1 and TACR1 methylation profiles for head and neck squamous cell carcinoma (HNSCC) tumors at diagnosis and follow-up and to evaluate their prognostic significance and value as a biomarker of recurrence. MATERIALS AND METHODS:TAC1 and TACR1 expression was measured in a panel of cell lines by quantitative RT-PCR. The TAC1 and TACR1 promoter methylation status was determined by quantitative methylation-specific PCR. RESULTS: Methylation was associated with TAC1 and TACR1 transcription inhibition. TAC1 methylation in 49/100 (49 %) of HNSCC tumor specimens significantly correlated with p16 methylation (P = 0.010), E-cadherin methylation (P = 0.041), galanin methylation (P = 0.037), and disease-free survival (P = 0.002). Stage III and IV patients manifesting TAC1 hypermethylation had significantly shorter survivals than did patients without TAC1 methylation (P = 0.022). TACR1 methylation in 34/100 (34 %) cases was significantly correlated with galanin methylation (P = 0.014) and GALR1 methylation (P = 0.004). TAC1 promoter hypermethylation was statistically correlated with reduced disease-free survival (log-rank test, P = 0.002). In multivariate logistic-regression analysis, methylation of TAC1 and of the gene pair TAC1 and TACR1 was associated with an odds ratio for recurrence of 3.35 (95 % CI, 1.37-8.19; P = 0.008) and 5.09 (95 % CI, 1.44-18.02; P = 0.011), respectively. CONCLUSION: CpG hypermethylation is a likely mechanism of TAC1 and TACR1 gene inactivation, supporting the hypothesis that TAC1 and TACR1 play a role in the tumorigenesis of HNSCC and that this hypermethylation may serve as an important biomarker.
Authors: Jana Jeschke; Leander Van Neste; Sabine C Glöckner; Mashaal Dhir; Marilia Freitas Calmon; Valérie Deregowski; Wim Van Criekinge; Ilse Vlassenbroeck; Alexander Koch; Timothy A Chan; Leslie Cope; Craig M Hooker; Kornel E Schuebel; Edward Gabrielson; Andreas Winterpacht; Stephen B Baylin; James G Herman; Nita Ahuja Journal: Epigenetics Date: 2012-07-01 Impact factor: 4.528
Authors: Tamotsu Kuroki; Francesco Trapasso; Sai Yendamuri; Ayumi Matsuyama; Hansjuerg Alder; Masaki Mori; Carlo M Croce Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: D L Van Dyke; M J Worsham; M S Benninger; C J Krause; S R Baker; G T Wolf; T Drumheller; B C Tilley; T E Carey Journal: Genes Chromosomes Cancer Date: 1994-03 Impact factor: 5.006
Authors: Hannah Lui Park; Myoung Sook Kim; Keishi Yamashita; William Westra; Andre Lopes Carvalho; Juna Lee; Wei-Wen Jiang; Jin Hyen Baek; Junwei Liu; Motonobu Osada; Chul-So Moon; Joseph A Califano; Masaki Mori; David Sidransky Journal: Int J Cancer Date: 2008-06-01 Impact factor: 7.396
Authors: Agnès Garnier; Matthias Ilmer; Kristina Becker; Beate Häberle; Dietrich VON Schweinitz; Roland Kappler; Michael Berger Journal: Oncol Lett Date: 2015-11-20 Impact factor: 2.967